Industry · Manufacture of basic pharmaceutical products and pharmaceutical preparations
Manufacture of pharmaceuticals, medicinal chemical and botanical products.
Companies and filings in the Manufacture of pharmaceuticals, medicinal chemical and botanical products industry, within the Manufacturing sector.
2,118
Companies
20
New filings
Latest filings
Live feed| Company | Document | Date | Actions |
|---|---|---|---|
|
Regulatory Filings
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 27 APRILE – 30 APRILE 2026 / TREASURY SHARES BUYBACK INFORMATION 27 APRIL – 30 APRIL 2026 PERIOD
|
May 04 | ||
|
Regulatory Filings
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
|
May 04 | ||
|
Regulatory Filings
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
|
May 04 | ||
|
Regulatory Filings
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
|
May 04 | ||
|
Regulatory Filings
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
|
May 04 | ||
|
Regulatory Filings
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
|
May 04 | ||
|
Regulatory Filings
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
|
May 04 | ||
|
Regulatory Filings
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND
CHANGES IN COMPOSITION OF BOARD COMMITTEES
|
May 04 | ||
|
Regulatory Filings
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
|
May 04 | ||
|
Regulatory Filings
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
|
May 04 | ||
|
Regulatory Filings
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
|
May 04 | ||
|
Regulatory Filings
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2026
|
May 04 | ||
|
Regulatory Filings
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
|
May 04 | ||
|
Regulatory Filings
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
|
May 04 | ||
|
Regulatory Filings
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
|
May 04 | ||
|
Regulatory Filings
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
|
May 04 | ||
|
Regulatory Filings
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
|
May 04 | ||
|
Regulatory Filings
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
|
May 04 | ||
|
Regulatory Filings
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
|
May 04 | ||
|
Regulatory Filings
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
|
May 04 |
Companies in this industry
| Company | Country | Market cap |
|---|---|---|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle stem cell function for DMD.
|
Canada | — |
|
16
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and development of novel medicines.
|
Canada | — |
|
3B
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious diseases and human genetics.
|
India | — |
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation immuno-oncology therapies.
|
Hong Kong | — |
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, production, and commercialization of biologics.
|
Cayman Islands | — |
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
|
United Kingdom | $104.34M |
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
|
United States of America | $475.29M |
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivation, manufacturing, and distribution.
|
Canada | — |
4SC AG
Biopharmaceutical company with no products under development or operational business.
|
Germany | $1.53M |
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
|
United States of America | $4.38M |
89bio, Inc.
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
|
United States of America | $2.20B |
Aardvark Therapeutics, Inc.
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
|
United States of America | $123.26M |
|
AA
Aarey Drugs & Pharmaceuticals Ltd
Manufactures APIs and chemical intermediates for global pharmaceutical sectors.
|
India | — |
|
AA
Aarti Drugs Limited
Produces APIs, pharma intermediates, and specialty chemicals for global markets.
|
India | — |
|
AA
Aarti Pharmalabs Limited
Manufacturer of APIs, intermediates, and xanthines with global CDMO capabilities.
|
India | — |
|
AA
AAYUSH WELLNESS LIMITED
Develops and markets herbal formulations, supplements, and nutraceuticals.
|
India | — |
|
AB
Ab&B Bio-Tech CO., LTD. JS
Biopharmaceutical company engaged in the R&D and commercialization of human vaccines and biologics.
|
Hong Kong | — |
Abbisko Cayman Limited
Clinical-stage biopharma focused on discovering and developing small molecule oncology therapies.
|
Cayman Islands | — |
|
AB
Abbott India Ltd.
Provides pharmaceutical solutions in gastroenterology, cardiology, and women's health.
|
India | — |
ABBOTT LABORATORIES
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
|
United States of America | $155.82B |
AbbVie Inc.
A research-based biopharmaceutical company developing and manufacturing medicines.
|
United States of America | $360.63B |
AbCellera Biologics Inc.
Discovers and develops antibody-based therapeutics using a proprietary platform.
|
Canada | $1.07B |
|
AB
AbClon Inc.
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
|
South Korea | — |
ABEONA THERAPEUTICS INC.
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
|
United States of America | $304.89M |
ABINGDON HEALTH PLC
A CDMO specializing in lateral flow assays, offering development to manufacturing services.
|
United Kingdom | $27.47M |
ABIONYX Pharma
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
|
France | $138.87M |
ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
|
France | $8.81B |
Abivax S.A.
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
|
United States of America | $8.42B |
ABL Diagnostics
Develops molecular diagnostic solutions for managing infectious diseases.
|
France | $52.09M |
Abliva
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
|
Sweden | $76.59M |
AB Science
Researches and develops protein kinase inhibitors for human and veterinary medicine.
|
France | $80.87M |
ABVC BIOPHARMA, INC.
Develops botanical drugs and medical devices for oncology, ophthalmology, and CNS.
|
United States of America | $33.58M |
ACADIA PHARMACEUTICALS INC
Biopharmaceutical company developing medicines for CNS disorders and rare diseases.
|
United States of America | $3.84B |
Access Bio, Inc.
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
|
India | — |
|
AC
Accretion Nutraveda Limited
Develops and manufactures pharmaceutical, nutraceutical, and Ayurvedic health solutions.
|
India | — |
|
AC
Accretion Pharmaceuticals Limited
Develops and manufactures therapeutic formulations across diverse medical segments.
|
India | — |
Acerus Pharmaceuticals Corporation
Specialty pharmaceutical company focused on developing and distributing innovative products for men's and women's health.
|
Canada | — |
ACHIEVE LIFE SCIENCES, INC.
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
|
United States of America | $210.83M |
|
AC
Achyut Healthcare Limited
Procures, trades, and manufactures pharmaceutical APIs and finished dosage formulations.
|
India | — |
AC Immune SA
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
|
Switzerland | $308.37M |
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
|
United States of America | $615.92M |
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
|
United States of America | $74.00M |
|
AC
ACRUX LIMITED
Develops and commercializes topical and transdermal drug delivery pharmaceutical products.
|
Australia | — |
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
|
France | $4.49M |
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
|
United States of America | $30.76M |
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
|
United States of America | $69.71M |
AcuCort AB
Develops user-friendly drug formulations for severe and acute allergic reactions.
|
Sweden | — |
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
|
United States of America | $176.87M |
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
|
United States of America | $6.79M |
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
|
United Kingdom | $14.55M |